We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Metabolon Participates in Expanded ALS Study

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Metabolon Participates in Expanded ALS Study"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Metabolon, Inc. has announced its continued participation in the ALS Association-sponsored study to identify biomarkers of amyotrophic lateral sclerosis (ALS, also called Lou Gehrig’s disease).

The Company participated in the initial pilot study, resulting in the discovery of novel biomarkers indicative of ALS and covered by a recently issued patent (US Patent 7,005,255).

The expanded study will increase study enrollment. Samples will be collected at 18 sites in the Translational Research Advancing Therapy for ALS (TREAT ALS)/Northeast ALS (NEALS) Clinical Trials Network. The Network is a partnership between The ALS Association and NEALS clinical research centers throughout the country, devoted to expanding clinical trials to treat the disease.

“A key unmet need in ALS clinical trials is a biomarker of the disease and its response to treatment,” according to Lucie Bruijn, Ph.D., Science Director and Vice President of The Association.

“We are excited about the continued funding of this project” says John Ryals, Ph.D, President and CEO of Metabolon. “Using our metabolomics platform, our initial studies discovered novel biomarkers potentially useful for diagnosing ALS. By expanding this study, we will be able to refine and validate those biomarkers, bringing us even closer to a clinical diagnostic.”

"Increasing the number of samples will accelerate our product development efforts in this area”, noted Mike Milburn, Metabolon’s Chief Scientific Officer. “We hope to make significant progress toward a clinical diagnostic over the next 12 months."